Jon Roffey
Head of Drug Discovery

PhD

Jon, a medicinal chemist by training, has more than 20 years drug discovery and commercial exploitation experience gained in the biotech and academic sectors. He has worked in therapeutic areas covering CNS, obesity, Parkinson’s disease and oncology, directly contributing to the development of multiple candidate drugs and late stage clinical agents. In 2015 Jon joined Cancer Research UK (CRUK) Commercial Partnerships most recently establishing CRUK’s largest drug discovery alliance, a major five year alliance with Celgene, to develop mRNA translation therapeutics.

Jon also played a major role in the development and commercialisation of CRUK’s CDK11 antibody drug conjugate platform technology, recently licensed to Glythera where he also a member of their Scientific Advisory Board. Jon was previously a senior group leader at CRT Discovery Laboratories where he led multidisciplinary project teams in the oncology setting against targets including a pioneer factor, aPKC, CDC7 and CDK11.

Earlier in his career Jon was at Spirogen, where he established the first proof of concept for Spirogen’s ADC platform, leading to the development of vadastuximab talirine and rovalpituzumab tesirine. Jon started his career in medicinal chemistry at Vernalis working on CNS targets for the treatment of obesity and Parkinson’s disease, delivering multiple candidate drugs for clinical evaluation. Jon completed a PhD in heterocyclic synthesis under the supervision of Prof. Chris Moody (University of Loughborough) and has co-authored over 40 patent applications and papers.